PROTECTING AGAINST THE FLU

  • OVERALL IMPACT OF THE FLU
  • TIPS FOR AVOIDING THE FLU
  • HEALTHCARE WORKERS AND THE FLU

OVERALL IMPACT OF THE FLU1

The flu is a common, potentially serious (even life-threatening) disease. The Centers for Disease Control and Prevention (CDC) estimates that every year in the United States

Impact of the flu

The flu is also a costly disease.2 For adults in the United States, the overall economic burden is
$83.3 billion, including 17 million lost workdays and2

Direct medical costs

Everyone 6 months of age and older who does not have contraindications should get an annual flu vaccine.3

  • The flu can be a serious disease that can lead to hospitalization and sometimes even death1
  • Anyone can develop the flu (even healthy individuals)4
  • A person can spread the influenza virus even in the absence of symptoms4
  • Getting a flu vaccine helps protect not only yourself but also your staff, patients, and everyone else around you5

TIPS FOR AVOIDING THE FLU FOR YOU, YOUR STAFF, AND YOUR PATIENTS5

In addition to getting a flu vaccine, there are ways you, your staff, and your patients can help
prevent the spread of the flu.

Avoid close contact
with people who are sick.
Cover your nose
and mouth
with a tissue when coughing or sneezing.
Avoid touching your eyes,
nose, and mouth.
The virus can be spread when a person touches something that is contaminated with the virus and then touches their eyes, nose, or mouth.
Stay home from work or school
when you are sick. Avoid close contact with others if you must go out.
Wash your hands with soap and water or use an alcohol-based hand sanitizer.
Practice good health habits.
Clean and disinfect frequently touched surfaces, especially when you are sick.
Get plenty of sleep, be physically active, manage your stress, drink plenty of
fluids, and eat nutritious food.

Click here to download important flu facts and tips for your office staff and patients.

HEALTHCARE WORKERS SHOULD GET AN ANNUAL FLU VACCINE6

Everyone is at risk of getting the flu. Healthcare workers can get the flu from (or spread it to) their
patients and coworkers. The CDC, the Advisory Committee on Immunization Practices, and the
Healthcare Infection Control Practices Advisory Committee strongly recommend an annual flu vaccine
for all people working in a healthcare setting, including:

  • Physicians, nurses, and other inpatient and outpatient care workers
  • Paramedics and other medical emergency responders
  • Workers in nursing homes and other long-term care facilities
  • Pharmacists and pharmacy technicians
  • Students in healthcare professions who will have contact with patients

HOW MANY HEALTHCARE WORKERS GOT AN ANNUAL FLU VACCINE?6,*

About 75% of all healthcare workers were vaccinated

of all healthcare workers were vaccinated

98% of healthcare workers were vaccinated

of healthcare
workers in settings
where the flu vaccine
was required were
vaccinated

WHICH HEALTHCARE WORKERS HAD THE HIGHEST RATES OF FLU VACCINATION?6,*

92% physicians 91% nurses 90% nurse-practioners and physician assistants 86% pharmaciststs

*Statistics from the 2013-2014 flu season.

References: 1. Seasonal Influenza Q&A. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/flu/about/qa/disease.htm. Accessed March 22, 2016. 2. Adult
Immunization. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/workplacehealthpromotion/evaluation/topics/immunization.html. Accessed March 22, 2016.
3. Grohskopf LA, Olsen SJ, Sokolow LZ, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices
(ACIP)–United States, 2014-15 Influenza Season. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6332a3.htm#Groups_
Recommended_Vaccination_Timing_Vaccination
. Updated August 15, 2014. Accessed March 22, 2016. 4. How Flu Spreads. Centers for Disease Control and Prevention Web site.
http://www.cdc.gov/flu/about/disease/spread.htm. Accessed March 22, 2016. 5. Prevention Strategies for Seasonal Influenza in Healthcare Settings. Centers for Disease Control and
Prevention Web site. http://www.cdc.gov/flu/professionals/infectioncontrol/healthcaresettings.htm. Accessed March 22, 2016. 6. Influenza Vaccination Information for Health Care
Workers. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/flu/healthcareworkers.htm. Accessed March 22, 2016.

HELP PROTECT YOUR PATIENTS AGAINST THE FLU WITH AFLURIA

seqirus

The product information presented on this site is for U.S. residents only. Afluria® Quadrivalent, Afluria®, and Seqirus are trademarks of Seqirus UK Limited or its affiliates. PharmaJet® and Stratis® are registered trademarks of PharmaJet Inc. Manufactured by: Seqirus Pty Ltd Parkville, Victoria, 3052, Australia Distributed by: Seqirus USA Inc. 25 Deforest Avenue, Summit, NJ 07901, USA © 2017 Seqirus USA Inc. www.seqirus-us.com MCC Code, Month 2017

AFLURIA® QUADRIVALENT (Influenza Vaccine) Important Safety Information

INDICATION
AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. AFLURIA QUADRIVALENT is approved for use in individuals 5 years of age and older.
CONTRAINDICATIONS
  • Severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine.
WARNINGS AND PRECAUTIONS
  • If Guillain-Barré Syndrome (GBS) has occurred within 6 weeks of previous influenza vaccination, the decision to give AFLURIA QUADRIVALENT should be based on careful consideration of the potential benefits and risks.
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.
  • Immunocompromised persons may have a diminished immune response to AFLURIA QUADRIVALENT.
ADVERSE REACTIONS
  • In adults 18 through 64 years, the most commonly reported injection-site adverse reaction when administered by needle and syringe was pain (≥40%). The most common systemic adverse events were myalgia and headache (≥20%).
  • In adults 65 years of age and older, the most commonly reported injection-site adverse reaction when administered by needle and syringe was pain (≥20%). The most common systemic adverse event was myalgia (≥10%).
  • In children 5 through 8 years, the most commonly reported injection-site adverse reactions when administered by needle and syringe were pain (≥50%), redness and swelling (≥10%). The most common systemic adverse event was headache (≥10%).
  • In children 9 through 17 years, the most commonly reported injection-site adverse reactions when administered by needle and syringe were pain (≥50%), redness and swelling (≥10%). The most common systemic adverse events were headache, myalgia, and malaise and fatigue (≥10%).

The safety experience with AFLURIA (trivalent formulation) is relevant to AFLURIA QUADRIVALENT because both vaccines are manufactured using the same process and have overlapping compositions:

  • In adults 18 through 64 years of age, the most commonly reported injection-site adverse reactions with AFLURIA (trivalent formulation) when administered by the PharmaJet Stratis Needle-Free Injection System were tenderness (≥80%), swelling, pain, redness (≥60%), itching (≥20%) and bruising (≥10%). The most common systemic adverse events were myalgia, malaise (≥30%), and headache (≥20%).

Please see accompanying full Prescribing Information for AFLURIA QUADRIVALENT.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.


AFLURIA® (Influenza Vaccine) Important Safety Information

INDICATION

AFLURIA is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. AFLURIA is approved for use in persons 5 years of age and older.

CONTRAINDICATIONS
  • Severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine.
WARNINGS AND PRECAUTIONS
  • Administration of CSL’s 2010 Southern Hemisphere influenza vaccine has been associated with increased rates of fever and febrile seizures in children predominantly below the age of 5 years as compared to previous years. Febrile events were also observed in children 5 through 8 years of age.
  • If Guillain-Barré Syndrome (GBS) has occurred within 6 weeks of previous influenza vaccination, the decision to give AFLURIA should be based on careful consideration of the potential benefits and risks.
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.
  • Immunocompromised persons may have a diminished immune response to AFLURIA.
ADVERSE REACTIONS
  • In children five through 17 years of age, the most common injection-site adverse reactions when administered by needle and syringe were pain (≥60%), redness (≥20%) and swelling (≥10%). The most common systemic adverse events were headache, myalgia (≥20%), irritability, malaise and fever (≥10%).
  • In adults 18 through 64 years of age, the most common injection-site adverse reactions when administered by needle and syringe were tenderness (≥60%), pain (≥40%), swelling (≥20%), and redness, itching (≥10%). The most common systemic adverse events were muscle aches (≥30%) headache and malaise (≥20%).
  • In adults 18 through 64 years of age, the most common injection-site adverse reactions when administered by the PharmaJet Stratis Needle-Free Injection System up to 7 days post-vaccination were tenderness (≥80%), swelling, pain, redness (≥60%), itching (≥20%) and bruising (≥10%). The most common systemic adverse events within this period were myalgia, malaise (≥30%), and headache (≥20%).
  • In adults 65 years of age and older, when administered by needle and syringe the most common injection-site adverse reactions were tenderness (≥30%) and pain (≥10%). No systemic adverse events occurred in ≥10% of subjects in this age group.

Please see accompanying full Prescribing Information for AFLURIA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

AFLURIA is a registered trademark of Seqirus UK Limited or its affiliates.